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Background
Participants in preventive HIV vaccine trials may experi-
ence social impact events (SIEs) related to study including
stigmatization and problems due to positive HIV tests
from vaccine-induced HIV antibody. Data are presented
on SIEs in the first Phase 2B HIV vaccine trial in South
Methods
From January 2007 through April 2009, 801 participants
enrolled in Phambili (HVTN 503) underwent standard-
ized assessments for SIE at scheduled time-points as well
as whenever reported by participants off-schedule.
Results
Forty six (5.7%) of study participants (28 women, 18
men) reported 51 SIEs. Most commonly reported (n 46,
90%) were negative reactions of family, friends, and co-
workers to the volunteer's study participation. Few events
pertained to employment (n 2), medical/dental care (n
2), or other categories. No participants reported problems
with education, housing, military service, travel/immigra-
tion, or health/life insurance. HIV testing was performed
outside of the study in relation to 2 events (health-care
related).
Most events followed participants' voluntary disclosure of
study participation (n 29, 56.9%), although in many
events (n 15, 29.4%), study participation was not
revealed.
Participants assessed most events (74.5%) as minimal
impact on quality of life (QOL), and the majority (58.5%)
as resolved. Of the 5 events with major impact on QOL, 3
involved personal relationships, 1 employment, and 1
other cause; none were resolved despite participant and
staff efforts. The majority of events (n 28, 55%) were
reported within the first month of enrollment, prior to the
scheduled assessment at month 3. Some events occurred
during screening.
Conclusion
Incidence of reporting was relatively low, with very few
major events reported. The majority of events were
reported very early in study.
Informing potential study participants about the risk of
SIE, and providing participants with assistance to prevent
or resolve events may be effective strategies in reducing
incidence and severity of SIEs.
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